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Alexandra Boehm,1 Barbara Walcherberger,1 Wolfgang R. Sperr,2 Stefan Wo¨hrer,1
Karin Dieckmann,3 Agathe Rosenmayr,4 Elisabeth Pernicka,5 Gottfried Fischer,4
Nina Worel,4 Gerlinde Mitterbauer,6 Ilse Schwarzinger,6 M. Mitterbauer,1
Oskar A. Haas,7 Klaus Lechner,2 W. Hinterberger,1 Peter Valent,2,8
Hildegard T. Greinix,1 Werner Rabitsch,1 Peter Kalhs1Although imatinib has become standard first-line therapy in chronic myelogenous leukemia (CML), allogeneic
hematopoietic stem cell transplantation (HSCT) is still considered to be an important treatment alternative
for patients with drug resistance or advanced disease. We retrospectively analyzed 175 adult CML patients
who underwent HSCTat our institution between 1983 and 2007, with the aim to compare outcomes in patient
subgroups and to identify prognostic variables. Themedian follow-up was 65months. The probability of overall
survival (OS) for all patientswas 62%, with a significant improvement seen in the imatinib-era (2001-2007) com-
pared to previous time periods (P\.05). Furthermore, a significantly better outcome for patients with chronic
phase CML compared to patients with accelerated or blast phase could be observed (P\ .05). Cumulative
incidence (CI) of treatment-related mortality (TRM) was 9.7% at 100 days and 1 year after HSCT. CI of relapse
was 5% at 1 year and 7.5% at 3 years after HSCT. Post-HSCToutcomewas not influenced by pretreatment ther-
apy with imatinib, donor type, or a conditioning regimen with total body irradiation (TBI). These data confirm
earlier observations and suggest that allogeneic HSCT is still an important treatment option for high-risk
patients with CML, and should thus remain an integral component in current and future treatment algorithms.
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6/j.bbmt.2010.06.019oncoprotein [1]. The clinical course is divided into
a chronic phase (CP), an accelerated phase (AP), and
a blast phase (BP) [2,3]. For more than 20 years, the
treatment of choice for all eligible patients was
allogeneic hematopoietic stem cell transplantation
(HSCT), whereas the standard therapy for all
ineligible patients was interferon-alpha (IFN-a). Dur-
ing the past 10 years, substantial progress has been
made in the treatment of patients with CML. A major
breakthrough has been the development and introduc-
tion of the BCR-ABL-targeting tyrosine kinase inhibi-
tor (TKI) imatinib and of second-generation TKIs,
including dasatinib and nilotinib [3-7]. The majority
of all patients in CP CML respond well to imatinib
and achieve durable cytogenetic complete remissions
(CRs), whereas patients with relapsed disease or
advanced phase often show a poor or only transient
response to TKIs [3-7]. In addition, imatinib and
other currently available TKIs apparently cannot
eradicate the disease at the stem cell level, and
primary, as well as acquired resistance to imatinib and133
134 Biol Blood Marrow Transplant 17:133-140, 2011A. Boehm et al.to second-generation TKIs, is an emerging problem in
the treatment of patients with CML [8-13].
HSCT is still an important salvage therapy, al-
though the total number of candidates has decreased
during the past decade, with a shift toward high-risk pa-
tients who still are referred quite frequently for HSCT.
Recently, HSCT was also recommended as the pre-
ferred second-line option after imatinib failure if a suit-
able donor is available [14]. Furthermore, with the
availability of reduced-intensity conditioning (RIC)
[15-17], improvement of antibiotic and antifungal
therapy [18,19], donor selection, and prevention and
therapy of graft-versus-host disease (GVHD) [20-23],
progress could be achieved in reducing morbidity and
mortality associated with HSCT.
The present study reports the analysis of 175 pa-
tients who received an allogeneic HSCT for CML in
our center. In these patients, we evaluated the clinical
outcome with overall survival (OS), treatment-related
mortality (TRM), relapse rate, and potential prognos-
tic variables.PATIENTS AND METHODS
Patients
Between 1983 and 2007, a total of 175 adult patients
with BCR-ABL-positive CML (females, n5 78; males,
n5 97) were referred for allogeneic HSCT to our insti-
tution. The median age was 38 years (range: 19-62
years). Disease- and transplant-specific characteristics
are shown in Table 1. Stem cell donors were HLA-
identical siblings (94 patients), matched unrelated do-
nors (URDs; 64 patients) and 1-allele-mismatched
URDs (17 patients). During the last 10 years, HSCT
with an URD was performed increasingly, whereas in
previous time periods (1983-2000) more sibling donors
were used. Histocompatibility typing and donor selec-
tion were performed as previously described [24,25].
At the time of HSCT, 122 patients were in first CP of
CML, 13 were in second or third CP, 25 were in AP,
and 15 patients were in BP. As expected, more patients
with advanced phase of the disease were transplanted
in recent years (2000 to 2007). Patients were
diagnosed according to published criteria [26]. Since
2001, patients have been classified according to the pro-
posal of the World Health Organisation [27].
One hundred thirty-one patients received bone
marrow (BM) stem cells, and 44 patients received
peripheral blood stem cells (PBSCs) mobilized by
recombinant human granulocyte colony stimulating
factor (rHuG-CSF). Patientswere hospitalized in isola-
tion rooms with laminar air flow or reverse isolation.
They received antimicrobial prophylaxis with oral
nonabsorbable antibiotics and Pneumocystis jirovecii pro-
phylaxis with trimethoprim/sulfamethoxazole. For
cytomegalovirus (CMV) prophylaxis, patients receivedacyclovir as described [28]. Packed red blood cells
(RBCs) were given to maintain hemoglobin concentra-
tions above 8.0 g/dL, and platelet transfusions were
given to keep the platelet count above 20  109/L. All
patients received CMV-negative blood products. Ap-
proved informed consentwas obtained fromall patients.
Conditioning Regimens and GVHD Prophylaxis
Myeloablative conditioning was performed in 166
patients. Of these, 126 patients received intravenous
(i.v.) cyclophosphamide (Cy) at 120mg/kg bodyweight
plus fractionated total body irradiation (TBI) (12 Gy
for related donor HSCT, and 13.2 Gy for URD
HSCT). One patient received i.v. etoposid 60 mg/kg
body weight and 13.2 Gy TBI. Thirty-nine patients
received i.v. Cy in the same dosage plus either oral bu-
sulfan at 16 mg/kg body weight or i.v. busulfan at 12.8
mg/kg body weight. RIC was performed in 9 patients
and consisted either of the FLAMSA (fludarabine, am-
sacrine, ARA-C, 4Gy of TBI, Cy, antithymocyte glob-
ulin [ATG]) protocol (4 patients), or fludarabine at 90
mg/m2 body surface area plus 2 Gy of TBI (5 patients)
[29]. RIC was performed in case of an advanced age
($60 years, n 5 4), or because of poor performance
status with severe comorbidities (n 5 5).
For GVHD prophylaxis, 162 patients received cy-
closporine A (CsA) and methotrexate (MTX) according
to the Seattle protocol [30], 9 patients received CsA and
mycophenolate mofetil [31], 3 patients received only
MTX, and 1 patient received CsA and methylpredniso-
lone.The clinical diagnosis ofGVHDwas confirmedby
biopsy and was clinically graded as 0 to IV for acute
GVHD (aGVHD), and as “none,” “limited,” or “exten-
sive” for chronic GVHD (cGVHD) [32,33].
Engraftment and Molecular Response
In all patients PBSC counts were determined on
a daily basis, starting 7 days beforeHSCTuntil hemato-
poietic engraftment. Absolute neutrophil counts
(ANCs) were calculated from leukocyte and differential
counts. BM aspirates/biopsies were performed before
HSCT, as well as on days 28 and 1 year after transplan-
tation. Engraftment was defined as the first of 3 days
with an ANC of at least 0.5  109/L, a stable platelet
count of at least 20 109/L, and RBC transfusion inde-
pendence. Engraftment of donor cells was documented
by cytogenetic analyses and amplification of highly
variable DNA regions (short tandem repeats) of differ-
ent sex-independent genes byPCRof recipient BMcells
before and 28 days after transplantation. Chromosome
analyses were performed from short-term BM cell
cultures using theG-banding technique. Chromosomal
abnormalities were described according to the Interna-
tional System for Human Cytogenetic Nomenclature
[34]. For serial chimerism analysis, unseperated PB,
CD31 and CD331 subsets, and granulocytes were
Table 1. Patients’ Characteristics I
Year of Transplantation
All Patients n 1983-1994 n 1995-2000 n 2001-2007 n
No. of patients 175 55 78 42
Median age (range) in years 38 (19-62) 35 (19-57) 39 (19-62) 39 (24-60)
Median time from diagnosis to HSCT(months) 14 (2-226) 14 (5-72) 14 (2-226) 14 (4-188)
Sex
Female 78 24 34 20
Male 97 31 44 22
Conditioning
Myeloablative with TBI 127 43 58 26
Myeloablative without TBI 39 12 18 9
RIC 9 0 2 7
Disease status at HSCT
CP 1 122 40 63 19
>CP 1 13 2 2 9
AP 25 10 8 7
BP 15 3 5 7
GVHD-Prophylaxis
CSA/methylprednisolone 1 1 0 0
MTX 3 3 0 0
CsA/MTX 162 51 76 35
CsA/MMF 9 0 2 7
Imatinib prior to HCT
Yes 32 0 1 31
No 143 55 77 11
Stem cell source
BM 131 55 61 15
PB 44 0 17 27
Gratwohl Score*
1+2 72 35 29 8
3+4 81 17 41 23
5+6 22 3 8 11
Donor HLA-identity
HLA-match 158 53 69 36
1-allele-mismatch 17 2 9 6
Donor type
Sibling 94 52 30 12
URD 81 3 48 30
HSCT indicates hematopoietic stem cell transplantation; TBI, total body irradiation; RIC, reduced intensity conditioning; CP, chronic phase; AP, accel-
erated phase; BP, blast phase; GVHD, graft-versus-host disease; MTX, methotrexate; CsA, cyclosporine A; MMF, mycophenolate mophetil; BM, bone
marrow; PB, peripheral blood; HLA, human leukocyte antigen; URD, unrelated donor.
*See [39].
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in patients receiving RIC. Monitoring of molecular re-
sponse by measurement of BCR-ABL transcript levels
was based on reverse-transcription polymerase chain
reaction (RT-PCR) every 3 months until a complete
molecular response was documented. After achieving
a complete molecular response, monitoring was per-
formed every 6 months. For BCR-ABL analysis, total
RNA was extracted after red cell lysis from 20 mL PB
or 5 mL BM using the Rneasy Mini Kit (Quiagen,
Hilden, Germany) according to the manufacturer’s
instructions. cDNA synthesis was performed using ran-
dom hexamer primers and MultiScribe Reverse Tran-
scriptase (Applied Biosystems, Foster City, CA, USA).
Real-timePCRamplificationofBCR-ABLusingnested
primers was performed as described [35]. Since 2001,
quantitative real-time qualative (Q-PCR) for BCR-
ABLand total ABL transcriptswere performed in dupli-
cates using the LightCycler 1.0 or 2.0 apparatus (Roche,
Indianapolis, IN, USA) and the M-bcr FusionQuant
Kit for the RT-QPCR analysis of M-bcr transcripts(Ipsogen,Marseille, France), according to the manufac-
turer’s instructions.Statistical Analysis
OS was calculated from the day of HSCT until
death from any cause. Patients who were alive or lost
for follow-up were censored. The probability of OS
was estimated using the Kaplan-Meier method. Poten-
tial prognostic factors for survival were examined in
univariate and multivariate analysis by Cox’s regres-
sion. TRM was defined as mortality after HSCT not
occurring because of relapse. The software package
SPSS 10.0 (SPSS Inc., Chicago, IL, USA) was used
for all these statistical analyses.
For outcome analysis, the proportional subdistri-
bution hazards’ regression model of Fine and Gray
was used [36]. To investigate the relation of relevant
covariables on GVHD, univariate competing risk re-
gressions were calculated. The incidence of GVHD
before day 100 after HSCT was defined as “acute”
Figure 1. Probability of overall survival (OS) for all CML patients
(n 5 175) performed in the years 1983-1994, 1995-2000, and 2001-
2007 (P\.05). Figure 2. Probability of overall survival (OS) for all CML patients
(n 5 175) according to the phase of the disease (P\.05).
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value\.05 were further applied in a multivariate com-
peting risk regression. For the outcome analysis of
relapse, the same covariables were studied and addi-
tionally, the previous incidence of GVHD (aGVHD
and, cGVHD, or 1 of them) was tested. These analyses
were performed using SAS 9.1 (SAS Institute, Inc.,
Cary, NC, USA) and R 2.8.1. (using cmprsk package).
Values of P \.05 were considered to be statistical
significant.
Definition of Relapse and Imatinib Failure
or Resistance
Relapse was defined as recurrence of Ph1
metaphases/BCR-ABL transcripts by cytogenetic/mo-
lecular analysis or hematologic signs of CML in PB or
BM after achievement of complete remission. Relapse
was defined as molecular if it occurred without hema-
tologic or clinical signs of disease. Relapse was defined
as hematologic if hematologic signs of CML preceded
or accompanied molecular evidence of relapse. Treat-
ment failure or resistance to imatinib were defined
according to institutional guidelines that are based
on the recommendations by the European Leukemia
Net (ELN) [37].Table 2. Cumulative Incidences (CIs) of TRM, GVHD, and
Relapse Rate
100 Days 1 Year 3 Years 5 Years after HCT
TRM 0.097 0.097 0.097 0.103
GVHD 0.526 0.663 0.663 0.663
Relapse 0.011 0.051 0.075 0.075
TRM indicates treatment-related mortality; GVHD, graft-versus-host
disease.RESULTS
Outcome and Survival
Apart from 1 patient, all engrafted, and currently
108 of the 175 patients (62%) are alive with a median
follow-up of 65 (range: 1-273) months. Significant im-
provement of OS was observed when comparing time
intervals over the last 25 years. For transplantations
performed in the years 1983-1994, 1995-2000, and2001-2007, OS was 50%, 63%, and 76%, respectively
(Figure 1, P\.05). OS for patients in different phases
of CML is shown in Figure 2. Significantly better OS
in patients with CP, compared to patients in AP or BP,
was observed. Between 1983 and 1994, 24% of all
CML patients were in AP or BP, between 1995 and
2000 17%, and between 2001 and 2007 33%. No dif-
ference of OS was found for patients with a sibling
compared to a URD. The cumulative incidence (CI)
for relapse was 5% 1 year after HSCT (Table 2), and
8% 3 and 5 years after HSCT (Table 2). Twenty-
three patients died as a consequence of cGVHD, 15
patients died from severe infections without cGVHD,
10 patients died because of toxicity and multiorgan
failure, 1 patient died from myocardial infarction,
and in 2 patients the exact cause of death remains
unknown. The cumulative incidence for TRM at 100
days and 1 year after HSCT was considerably low
and amounted to 10%. The cumulative incidence for
GVHD at 100 days after HSCT was 53%, and at 1
year and at 5 years 66% (Table 2).Outcome of Patients with Imatinib
Prior to HSCT
In the years 2000 to 2007, 32 patients received ima-
tinib prior to HSCT (Table 3). Imatinib treatment
ranged from 1 to 48 months, and patients were
Table 3. Patients’ Characteristics II
Imatinib Prior
to HSCT n
No Imatinib
Prior to HSCT n
No. of patients 32 143
Median age (range) in years 42 (24-60) 38 (19-62)
Median time from diagnosis
to HSCT(months)
15 (4-188) 13 (2-226)
Imatinib duration (months) 8 (1-48) d
Gender
Female 15 63
Male 17 80
Conditioning
Myeloablative with TBI 21 106
Myeloablative without TBI 4 35
RIC 7 2
Disease status at HSCT
CP 1 12 110
>CP 1 7 6
AP 7 18
BP 6 9
GVHD-Prophylaxis
CSA/methylprednisolone 0 1
MTX 0 3
CsA/MTX 25 137
CsA/MMF 7 2
Stem cell source
BM 6 125
PB 26 18
Gratwohl Score*
1+2 3 69
3+4 13 68
5+6 16 6
Donor HLA-identity
HLA-match 26 132
1-allele-mismatch 6 11
Donor type
Sibling 7 87
URD 25 56
HSCT indicates hematopoietic stem cell transplantation; TBI, total body
irradiation; RIC, reduced-intensity conditioning; CP, chronic phase; AP,
accelerated phase; BP, blast phase; GVHD, graft-versus-host disease;
MTX, methotrexate; CsA, cyclosporine A; MMF, mycophenolate
mophetil; BM, bone marrow; PB, peripheral blood; HLA, human leuko-
cyte antigen; URD, unrelated donor.
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The reasons for referral forHSCTwere imatinib failure
(n5 24), imatinib toxicity (n5 2), and high-risk disease
with an availableHLA-matched donor (n5 6).Twenty-
one of 32 patients (66%) are still alive with a median
follow-up of 19 (range: 1-74) months. Three patients
died because of relapse, and 8 patients died because of
TRM (GVHD with or without infection). OS
(Figure 3), and TRM were not different from patients
who did not receive imatinib, whereas the incidence of
GVHDwas significantly increased in the imatinib group
(hazard ratio [HR]5 2.21 [1.22;3,99], P5 .009), as as-
sessed with multivariate competing risk regression.
The median Karnofsky performance score for all
patients alive at 1 year after HSCT was 80% (range:
70%-100%).
Analysis of Patients with Relapse after HCT
Twenty-eight of 175 patients (17%) relapsed after
allogeneic HSCT at a median of 15 months (range: 3-
144) after HSCT, and 2 patients had persistent disease.Fifteen patients had hematologic relapse, 5 patients
hadmolecular relapse, and8patients hadextramedullary
relapse, 1 of these with involvement of the central ner-
vous system (CNS). Thirteen of the patients with hema-
tologic relapse were transplanted in the years 1983 to
2000; thus, these patients had no quantitative monitor-
ing of BCR-ABL. Further therapy consisted of donor
lymphocyte infusion (DLI) in 12 patients, 3 patients re-
ceived a second HSCT, 10 patients received imatinib, 1
patient had local radiation, and 4 patients did not receive
further treatment. The patient with CNS relapse re-
ceived intrathecal cytarabine and dasatinib and entered
a cytogeneticCR.Fifteenpatientswith relapsedied; uni-
variate analysis revealed the presence of BP at the time of
HSCTas a significant prognostic factor for the riskof re-
lapse. No significant influence of GVHD was found;
however, the previous incidence of aGVHD and/or
cGVHD showed a tendency to protect from relapse
(HR5 0.52 [0.25; 1.09], P5 .0842).
Outcome of Patients with Reduced-Intensity
Conditioning
Nine patients received RIC; 5 of these patients were
in first (n5 3) or second (n5 2) CP of the disease, 1 was
inAP, and3patientswere inBP.Fivepatients died, 2 be-
cause of persistent disease, 2 because of relapse and1had
an infection with severe cGVHD. Four patients alive
have been in continuous molecular CR, for a median
of 51 (range: 37-65) months after HSCT. Of note, all
achieved a complete donor chimerism that has been sus-
tained.
Analysis of BM versus PBSCs
As depicted in Table 1, 131 patients received BM
and 44 PBSCs. We could find a slight but not statisti-
cally significant difference in OS (Figure 4). In further
outcome analysis with competing risk regressions, no
significant influence of the stem cell source on the oc-
currence of GVHD or the risk of relapse was found.
Analysis of Prognostic Variables for OS,
Incidence of GVHD, and Risk of Relapse
To determine the influence on OS, several possible
and known prognostic factors were investigated in uni-
variate andmultivariate analyses. In detail, we evaluated
sex, age at HSCT, TKI prior to HCT, phase of the dis-
ease at HSCT, donor type, HLA-match, Gratwohl
score, stem cell source, TBI for conditioning therapy,
and aGVHD. In our group of CML patients, we
could not identify an independent risk factor indicating
a favorable outcome concerning OS.
Furthermore, we determined the influence of the
same covariates on the occurrence of aGVHD/
cGVHD or the risk of relapse. A TKI prior to
HSCT, the presence of a later than first CP at HSCT
and a sibling donor increased the risk of GVHD, but
Figure 4. Probability of overall survival (OS) for CML patients with
bone marrow derived stem cells (n5 131) or peripheral blood derived
stem cells (n 5 44).
Figure 3. Cumulative incidence probability of overall survival (OS) for
CML patients with (n5 32) or without (n5 143) imatinib prior to HCT.
138 Biol Blood Marrow Transplant 17:133-140, 2011A. Boehm et al.only a TKI prior to HSCT remained significant in the
multivariate model (HR5 2.21 [1.22; 3.99], P5 .009).
Concerning the risk of relapse, no significant influence
of GVHD was found, although the previous incidence
of aGVHD and/or cGVHD showed a tendency to pro-
tect from relapse (HR 5 0.52 [0.25; 1.09], P 5 .0842).
Only BP at HSCT increased the risk of relapse signifi-
cantly in univariate analysis.
In a subanalysis of 57 consecutive patients between
2001 and 2007, based on a previously published study
[38], we also investigated the prognostic impact of
serum b-2-microglobulin levels and ferritin on out-
come and survival; no statistically significant effect
could be found.DISCUSSION
Allogeneic HSCT is still considered to be the only
curative treatment for CML, although the total number
of eligible patients has decreased since the introduction
of TKIs. We analyzed 175 patients with CML who
were transplanted at a single center between 1983 and
2007 with a median follow-up of 65 (range: 1-273)
months. We assessed OS, CI of GVHD, TRM, relapse
rate, and possible prognostic variables, to define the po-
tential role of HSCT in the TKI era.
To analyze the development of outcome and sur-
vival, we divided our cohort into 3 groups, depending
on the time period HSCT was performed: 1983-
1994, 1995-2000, and 2001-2007.OS showed a distinct
improvement over time ranging from 50% in the
early group to 76% (P \.05) in the recently trans-
planted group even though the number of transplant
candidates with the AP of the disease increased during
the past decade. This development in the outcome
may be attributable to a number of different factors,including improvements in high-resolution HLA-
typing, less toxicity of pretransplantation treatment,
improvement of supportive care, better antiinfectious
therapy, and improved overall management of GVHD.
In our cohort we had 32 patients who received
imatinib prior to HSCT. The median time interval
fromdiagnosis toHSCTwas 15months.These patients
were transplanted primarily because of imatinib failure
with loss of molecular response or cytogenetic remis-
sion. Six patients were referred to our institution
because of high-risk disease according to the Gratwohl
score [39] ranging between 4 and 6. Outcome and
TRM did not differ when comparing patients who had
received imatinib prior toHSCTwith all other patients.
However, in furtheroutcomeanalysis,we found that im-
atinib prior to HSCT increased the CI of GVHD but
had no negative influence on OS. This data are only in
parts consistent with previously published results [40],
but interpretation is limited because of the small cohort
of imatinib pretreated patients in our group. One possi-
ble explanation for this discrepancy is a higher rate of
skin only GVHD in patients with imatinib (5 of 32
patients5 16%) compared to patients without imatinib
prior to HSCT (3 of 143 5 2% patients), which shows
a better response to treatment, thereby not affecting
survival. Further immunologic investigations were not
performed. With regard to the fact that imatinib has
become the standard first-line treatment for CML
patients, it seems rather important to emphasize that
prior therapy with a TKI does not increase TRM.
Also, provocative results have been published byOehler
et al. [41], who showed that the best transplant results
may be obtained in patients responding to imatinib
compared to non- or suboptimal responders prior to
transplantation. These findings clearly show that close
molecular monitoring is necessary and that rapid
changes of therapeutic strategies (eg, performing
Biol Blood Marrow Transplant 17:133-140, 2011 139HCT in CMLHSCT) might improve patients’ outcome. Also, inter-
esting results showed a recent report published by Saus-
sele et al. [14], who found an OS at 3 years after
allogeneic HSCT for patients with imatinib failure in
first CP of 94%.These are excellent results, and in their
group of patients with advanced phase of CMLOS was
still 59%. If these results can be confirmed, allogeneic
HSCT will clearly be recommended as the preferred
second-line treatment option after failure of first-line
TKI therapy. Also, subclones resistant to imatinib may
be eradicated with HSCTmore effectively at an earlier
time point because of the plasticity of CML stem cells
with rapid outgrowth ofmoremalignant subclones.The
next step was to focus on different prognostic factors
concerning OS. In our group of patients, we could not
find a statistical significant predictor of favorable sur-
vival, additionally we were unable to show a prognostic
impact of elevated b2-microglobulin, a parameter that
has recently been described to be prognostic in non-
transplant patients treated with imatinib [38]. It also
seems that the Gratwohl Score [39] is more applicable
for “historic” patients who did not receive any TKIs
prior toHSCTbecause of changes in patients’ selection
forHSCT. Therefore, it will be necessary for the future
to establish new prognostic scores for CML patients.
With the introduction of RIC in the last years
toxicity and the risk of TRM could be decreased for
patients with substantial comorbidity and/or higher
age and/or high-risk disease. To focus on the selection
of the ideal conditioning therapy, our number of
patients was too small for any solid conclusion. Never-
theless, with the availability of RIC, HSCT can be
offered to a broader spectrum of patients.
Regarding stem cell source and donor type (related
versus unrelated donor) our results for OS, TRM, and
occurrence of GVHD were comparable.
The CI of recurrence of CML after transplanta-
tion was 5% at 1 year after HSCT and 8% at 3 years.
Fifty percent of relapsed patients had hematologic
relapse, 23% hadmolecular, and 27% had extramedul-
lary relapse. Further systemic therapy consisted either
of imatinib or DLIs, or imatinib and DLIs. Fifteen pa-
tients died all in all, with a trend toward better survival
of patients who received a TKI.
Finally, according to these observations, we con-
clude that HSCT remains an important treatment op-
tion for patients with failure/resistance (especially in
patients with poor-risk mutations, eg, T315I mutation)
to TKIs, primary advanced phase of the disease or pro-
gression to AP/BP under TKI treatment.ACKNOWLEDGMENTS
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